Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
64 participants
INTERVENTIONAL
2020-01-02
2021-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inhaled Budesonide in Transient Tachypnea of the Newborn
NCT04758078
Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn
NCT01858129
Role of Salbutamol and Furosemide in TTN
NCT03208894
Assessment Of Dose-Dependent Immunomodulatory Effect Of Alveofact With or Without Steroisd In Neonatal RDS
NCT06367881
Nebulized Furosemide in Premature Infants With Bronchopulmonary Dysplasia - A Cross Over Pilot Study of Its Efficacy and Safety
NCT03946891
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Furosemide
Patients will receive nebulised furosemide
Furosemide
Patients will receive nebulised furosemide solution 1 mg/kg
Placebo
Patients will receive nebulised 0.9% saline
Placebo
Patients will receive nebulised 0.9% saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Furosemide
Patients will receive nebulised furosemide solution 1 mg/kg
Placebo
Patients will receive nebulised 0.9% saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* on the first day of life
* with the clinical diagnosis of Transient Tachypnoea
* need for CPAP \>6 hours to obtain the oxygen saturation \>92%
Exclusion Criteria
* Intubation and mechanical ventilation before Inclusion in the trail
* Malformation and any other disease with disturb of respiratory system
1 Day
1 Day
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Makassed General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mariam Rajab
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mariam Rajab, MD
Role: PRINCIPAL_INVESTIGATOR
Makassed General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Makassed General Hospital
Beirut, , Lebanon
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18122018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.